Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission.
Kedra J, Dieudé P, Giboin C, Marotte H, Salliot C, Schaeverbeke T, Perdriger A, Soubrier M, Morel J, Constantin A, Dernis E, Royant V, Salmon JH, Pham T, Gottenberg JE, Pertuiset E, Dougados M, Devauchelle-Pensec V, Gaudin P, Cormier G, Goupille P, Mariette X, Berenbaum F, Alcaix D, Rouidi SA, Berthelot JM, Monnier A, Piroth C, Lioté F, Goëb V, Gaujoux-Viala C, Chary-Valckenaere I, Hajage D, Tubach F, Fautrel B; CRI‐IMIDIATE clinical research network. Kedra J, et al. Among authors: goupille p. Arthritis Rheumatol. 2024 Apr;76(4):541-552. doi: 10.1002/art.42752. Epub 2024 Jan 25. Arthritis Rheumatol. 2024. PMID: 37942714 Clinical Trial.
Efficacy of Janus kinase inhibitors in rheumatoid arthritis.
Langbour C, Rene J, Goupille P, Carvajal Alegria G. Langbour C, et al. Among authors: goupille p. Inflamm Res. 2023 May;72(5):1121-1132. doi: 10.1007/s00011-023-01717-z. Epub 2023 Apr 22. Inflamm Res. 2023. PMID: 37087519 Review.
Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative.
Ruyssen-Witrand A, Caillet-Portillo D, Najm A, Fogel O, Baillet A, Claudepierre P, Conort O, Dernis E, Fayet F, Gossec L, Goupille P, Hudry C, Letarouilly JG, Lukas C, Marotte H, Molto A, Pouplin S, Senbel E, Sordet C, Tournadre A, Truchetet ME, Wendling D, Dougados M. Ruyssen-Witrand A, et al. Among authors: goupille p. Joint Bone Spine. 2024 Apr 9;91(5):105733. doi: 10.1016/j.jbspin.2024.105733. Online ahead of print. Joint Bone Spine. 2024. PMID: 38604594
Can we consider a pre-clinical state of axial spondyloarthritis?
Wendling D, Goupille P, Verhoeven F, Prati C. Wendling D, et al. Among authors: goupille p. Joint Bone Spine. 2024 Apr 4;91(4):105722. doi: 10.1016/j.jbspin.2024.105722. Online ahead of print. Joint Bone Spine. 2024. PMID: 38582360 No abstract available.
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
Dougados M, Lardy-Cléaud A, Desfleurs E, Claudepierre P, Goupille P, Ryussen-Witrand A, Saraux A, Tournadre A, Wendling D, Lukas C. Dougados M, et al. Among authors: goupille p. RMD Open. 2024 Feb 29;10(1):e003942. doi: 10.1136/rmdopen-2023-003942. RMD Open. 2024. PMID: 38428974 Free PMC article.
301 results